var path='https://www.tickertech.net'; function heading(heading) { document.write('
'+heading+' |
'+ ''+ ' |
'); } function hiLite(imgDocID,imgObjName) { document.images[imgDocID].src = eval(imgObjName + ".src"); } function showStatus(toshow) { window.status = toshow; } function checkChoose() { if (document.choose.ticker.value == "") { alert("Please enter symbols before clicking the go button"); return false; } else return true; } function popJT(url,name){ var xwid = screen.width; xwid = xwid - 10; javaticker = window.open(url,name,'width='+xwid+',height=100,resizable=yes,scrollbars=no,toolbar=no,location=no,directories=no,status=yes,menubar=no'); javaticker.opener.name="opener"; //javaticker.moveTo(0,30); } var allow = 0; var ref = ""+location; if ((ref.indexOf("cryptocurrencieschannel.com") > 0) || (ref.indexOf("cefchannel.com") > 0) || (ref.indexOf("bdcinvestor.com") > 0) || (ref.indexOf("tickertech.com") > 0) || (ref.indexOf("xxxx:") > 0) || (ref.indexOf("javascript:") > 0) || (ref.indexOf("filseclab.com") > 0) || (ref.indexOf("msnscache.com") > 0) || (ref.indexOf("toolbar.google.com") > 0) || (ref.indexOf("etfchannel.com") > 0) || (ref.indexOf("marketnewsvideo.com") > 0) || (ref.indexOf("news.google.com") > 0) || (ref.indexOf("dividendchannel.com") > 0) || (ref.indexOf("www.google.com") > 0) || (ref.indexOf("energystockchannel.com") > 0) || (ref.indexOf("metalschannel.com") > 0) || (ref.indexOf("portfoliochannel.com") > 0) || (ref.indexOf("canadastockchannel.com") > 0) || (ref.indexOf("theonlineinvestor.com") > 0) || (ref.indexOf("investhelp.com") > 0) || (ref.indexOf("preferredstockchannel.com") > 0) || (ref.indexOf("stockoptionschannel.com") > 0) || (ref.indexOf("holdingschannel.com") > 0) || (ref.indexOf("tickertech.net") > 0) || (ref.indexOf("historicalstockprice.com") > 0) || (ref.indexOf("splithistory.com") > 0) || (ref.indexOf("stocksplithistory.com") > 0) || (ref.indexOf("google.c") > 0) || (ref.indexOf("208.71.46.190") > 0) || (ref.indexOf("search.yahoo") > 0) || (ref.indexOf("sharesoutstandinghistory.com") > 0) || (ref.indexOf("marketcaphistory.com") > 0) || (ref.indexOf("ytdreturn.com") > 0) || (ref.indexOf("averageannualreturn.com") > 0) || (ref.indexOf("redinews.com") > 0) || (ref.indexOf("technicalanalysischannel.com") > 0) || (ref.indexOf("stockdma.com") > 0) || (ref.indexOf("stockrsi.com") > 0) || (ref.indexOf("stockmacd.com") > 0) || (ref.indexOf("topdividends.com") > 0) || (ref.indexOf("monthlydividendpayingstocks.com") > 0) || (ref.indexOf("nextearningsdate.com") > 0) || (ref.indexOf("pastearnings.com") > 0) || (ref.indexOf("historicalperatio.com") > 0) || (ref.indexOf("historicalearnings.com") > 0) || (ref.indexOf("webcache.googleusercontent.com") > 0)) { allow = 1; } function ShowTTIPage() { if (allow) { document.write('\n'); } if (allow) { document.write('
\n'); } if (allow) { document.write('4/30 - 8:00 AM \; \; | \n'); } if (allow) { document.write('INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer\'s Disease Trial who Continue to Receive XPro Under Compassionate Use for Over Three Years | \n'); } if (allow) { document.write('
4/29 - 8:00 AM \; \; | \n'); } if (allow) { document.write('INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer | \n'); } if (allow) { document.write('
4/25 - 9:00 AM \; \; | \n'); } if (allow) { document.write('INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | \n'); } if (allow) { document.write('
4/23 - 8:02 AM \; \; | \n'); } if (allow) { document.write('INmune Bio Inc. Announces 24-Month Stability Validation of XPro for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay | \n'); } if (allow) { document.write('
4/22 - 8:00 AM \; \; | \n'); } if (allow) { document.write('INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering | \n'); } if (allow) { document.write('
4/8 - 8:02 AM \; \; | \n'); } if (allow) { document.write('INmune Bio Inc. Presents Data on INB03\'s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024 | \n'); } if (allow) { document.write('
3/28 - 4:02 PM \; \; | \n'); } if (allow) { document.write('INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update | \n'); } if (allow) { document.write('
3/26 - 4:01 PM \; \; | \n'); } if (allow) { document.write('INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28 | \n'); } if (allow) { document.write('
3/13 - 8:00 AM \; \; | \n'); } if (allow) { document.write('INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy | \n'); } if (allow) { document.write('
3/5 - 8:00 AM \; \; | \n'); } if (allow) { document.write('INmune Bio Reports Significant EEG Improvement in Alzheimer\'s Patients Treated with XPro | \n'); } if (allow) { document.write('
2/12 - 9:00 AM \; \; | \n'); } if (allow) { document.write('INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference | \n'); } if (allow) { document.write('
2/6 - 9:02 AM \; \; | \n'); } if (allow) { document.write('INmune Bio to Participate in Baird\'s Biotech Discovery Series Webcast on February 13, 2024 | \n'); } if (allow) { document.write('
1/30 - 8:00 AM \; \; | \n'); } if (allow) { document.write('INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer\'s Disease Program | \n'); } if (allow) { document.write('
1/2 - 8:00 AM \; \; | \n'); } if (allow) { document.write('INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune in Patients with Metastatic Castration-Resistant Prostate Cancer | \n'); } if (allow) { document.write('
\n'); } if (allow) { document.write(' |